Blue Barn Wealth LLC Reduces Stock Position in Haleon plc (NYSE:HLN)

Blue Barn Wealth LLC cut its stake in shares of Haleon plc (NYSE:HLN) by 33.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 10,390 shares of the company’s stock after selling 5,152 shares during the period. Blue Barn Wealth LLC’s holdings in Haleon were worth $99,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sierra Ocean LLC purchased a new position in shares of Haleon in the 4th quarter worth about $26,000. Versant Capital Management Inc raised its stake in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Haleon in the 4th quarter worth approximately $35,000. Toronto Dominion Bank boosted its holdings in Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after acquiring an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in shares of Haleon during the fourth quarter valued at about $39,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Price Performance

NYSE HLN opened at $10.55 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The firm has a market capitalization of $47.74 billion, a P/E ratio of 31.01, a P/E/G ratio of 2.82 and a beta of 0.28. The firm’s fifty day simple moving average is $9.63 and its two-hundred day simple moving average is $9.85.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.